Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
2.30
Dollar change
+0.01
Percentage change
0.44
%
Index- P/E- EPS (ttm)-3.96 Insider Own19.21% Shs Outstand6.19M Perf Week12.20%
Market Cap14.24M Forward P/E- EPS next Y-1.49 Insider Trans0.00% Shs Float5.00M Perf Month1.77%
Income-19.13M PEG- EPS next Q-0.79 Inst Own7.96% Short Float0.60% Perf Quarter86.99%
Sales0.32M P/S44.49 EPS this Y50.42% Inst Trans-21.22% Short Ratio0.20 Perf Half Y66.67%
Book/sh2.80 P/B0.82 EPS next Y15.82% ROA-82.35% Short Interest0.03M Perf Year-49.78%
Cash/sh2.72 P/C0.85 EPS next 5Y- ROE-95.28% 52W Range0.79 - 4.92 Perf YTD81.10%
Dividend Est.- P/FCF- EPS past 5Y-76.13% ROI-126.36% 52W High-53.25% Beta1.21
Dividend TTM- Quick Ratio6.40 Sales past 5Y34.47% Gross Margin45.73% 52W Low191.14% ATR (14)0.21
Dividend Ex-Date- Current Ratio6.40 EPS Y/Y TTM11.60% Oper. Margin-6178.12% RSI (14)53.32 Volatility8.58% 8.94%
Employees6 Debt/Eq0.02 Sales Y/Y TTM424.23% Profit Margin-5903.12% Recom1.00 Target Price17.50
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q19.53% Payout- Rel Volume0.10 Prev Close2.29
Sales Surprise- EPS Surprise24.71% Sales Q/Q991.33% EarningsMar 27 AMC Avg Volume149.44K Price2.30
SMA203.23% SMA50-2.22% SMA20016.65% Trades Volume14,636 Change0.44%
Mar-27-24 10:53PM
04:15PM
Mar-07-24 08:30AM
Feb-28-24 04:05PM
Feb-15-24 09:55AM
07:55AM Loading…
Feb-07-24 07:55AM
Jan-29-24 09:05AM
Jan-22-24 12:00PM
Jan-16-24 04:05PM
Dec-19-23 08:30AM
Dec-04-23 08:35AM
Nov-14-23 04:30PM
Nov-07-23 09:28AM
08:00AM
Oct-16-23 07:00AM
08:30AM Loading…
Oct-04-23 08:30AM
Sep-20-23 08:30AM
Aug-24-23 08:30AM
Aug-22-23 08:05AM
Aug-21-23 08:30AM
Aug-17-23 08:30AM
Aug-15-23 11:47PM
Aug-14-23 04:20PM
Aug-07-23 08:05AM
Jul-17-23 04:05PM
Jun-29-23 09:29AM
Jun-22-23 08:05AM
Jun-21-23 08:05AM
May-30-23 08:05AM
May-24-23 12:04PM
06:11AM Loading…
May-17-23 06:11AM
May-16-23 07:45AM
May-15-23 08:30AM
May-09-23 07:15AM
May-08-23 08:05AM
May-04-23 08:05AM
May-02-23 03:30PM
Apr-26-23 08:00AM
Apr-24-23 09:00AM
Apr-21-23 08:30AM
Apr-07-23 10:25PM
Mar-31-23 08:22AM
Mar-23-23 05:15PM
Mar-21-23 08:00AM
Mar-16-23 08:30AM
Mar-15-23 08:35AM
Mar-08-23 08:30AM
Feb-15-23 04:05PM
Feb-08-23 01:00PM
Jan-27-23 04:05PM
Jan-25-23 01:00PM
08:35AM
08:05AM
Dec-12-22 04:05PM
Dec-07-22 04:05PM
Nov-22-22 08:00AM
Nov-14-22 05:45PM
Nov-10-22 05:00AM
Nov-08-22 08:00AM
Nov-07-22 08:00AM
Oct-12-22 08:00AM
Sep-21-22 04:05PM
Sep-15-22 08:00AM
Sep-13-22 12:15PM
Sep-08-22 08:30AM
Sep-01-22 04:05PM
Aug-26-22 08:00AM
Aug-23-22 08:00AM
Aug-12-22 04:55PM
Aug-08-22 08:30AM
Jun-13-22 08:00AM
May-16-22 05:00PM
May-10-22 08:05AM
May-09-22 04:05PM
Apr-21-22 04:05PM
Apr-13-22 11:45AM
Apr-06-22 11:37AM
08:00AM
Mar-31-22 05:00PM
Mar-28-22 08:00AM
Mar-25-22 08:00AM
Mar-23-22 08:00AM
Mar-08-22 08:00AM
Jan-05-22 08:30AM
Nov-29-21 08:05AM
Nov-15-21 05:30PM
Oct-27-21 08:05AM
Oct-19-21 08:05AM
Oct-04-21 09:57AM
08:05AM
Sep-23-21 08:05AM
Sep-07-21 08:00AM
Aug-16-21 04:45PM
Jul-26-21 10:09AM
08:42AM
Jun-18-21 06:45PM
Jun-16-21 08:00AM
06:57AM
Jun-15-21 07:40PM
May-25-21 08:00AM
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.